Stay updated with breaking news from Not Estimable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Talquetamab is a bispecific T-cell engaging antibody that binds to CD3 The Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that
News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 Investor Relations: Raychel... | June 5, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of...
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from...
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at ASCO First presentation of phase 1 data from a cohort